当飞利肝宁联合苦参素抗肝纤维化123例临床观察

目的：观察当飞利肝宁联合苦参素治疗乙型肝炎病毒感染的不同肝病患者肝纤维化的疗效。方法：采用RIA法，分别检测应用当飞利肝宁联合苦参素治疗前和治疗6个月后123例不同肝病患者血清肝纤维化指标含量，另31例慢性乙型肝炎患者采用单一苦参素治疗，用同法检测其血清肝纤维化指标含量。结果：123例不同肝病患者中乙型肝炎病毒携带者、慢性乙型肝炎、代偿期肝硬化患者治疗后与治疗前比较肝纤维化指标明显下降（P〈0．05或P〈0．01），失代偿期肝硬化患者治疗后各项指标无明显变化（P〉O．05）。当飞利肝宁联合苦参素治疗后，慢性乙型肝炎患者的肝纤维化指标含量明显下降（P〈0．01），且较单一苦参素治疗疗效更好（P〈0．05）。结论：当飞利肝宁联合苦参紊治疗可使乙型肝炎病毒携带者、慢性乙型肝炎、代偿期肝硬化患者血清肝纤维化指标含量显著下降，阻止或延缓失代偿期肝硬化患者病变进程，且抗慢性乙型肝炎纤维化疗效明显优于单用苦参素。

Clinical Observation on Dangfei Liganning Combined with Matrine in Treatment of Hepatic Fibrosis in 123 Cases

Objective:To observe the therapeutic effect of Dangfei Liganning combined with Matrine on hepatic fibrosis in patients of different hepatic diseases infected by hepatitis B virus.Methods:Determine serum hepatic fibrosis indexes before and 6 months after treatment with RIA in 123 cases of different hepatic diseases treated with Dangfei Liganning combined with Matrine,and 31 cases of chronic hepatitis B treated with simple Matrine.Results:Of the 123 cases of different hepatic diseases,hepatic fibrosis indexes in hepatitis B virus carriers,chronic hepatitis B patients and the patients of liver cirrhosis at compensatory phase decreased significantly(P<0.05 or P<0.01) after treatment,but the indexes in the patients of liver cirrhosis at decompensatory phase did not significantly change(P>0.05).After treatment with Dangfei Liganning combined with Matrine,the hepatic fibrosis indexes in the patients of chronic hepatitis B significantly decreased(P<0.01) with a better therapeutic effect than that of simple Matrine(P<0.05).Conclusion:Dangfei Liganning combined with Matrine can significantly decrease hepatic fibrosis indexes in hepatitis B virus carriers,patients of chronic hepatitis B and liver cirrhosis at compensatory phase,arresting or delaying development of lesion in the patient of liver cirrhosis at the decompensatory phase,with a significantly better therapeutic effect than simple Matrine.